tradingkey.logo

Monte Rosa soars after $5.7 billion licensing deal with Novartis

ReutersSep 15, 2025 2:37 PM

** Shares of Monte Rosa Therapeutics GLUE.O jump 35.6% to $6.52

** Stock set for its biggest one-day pct. gain in over 10 months, if gains hold

** Company says it has entered into an agreement to collaborate with Swiss drugmaker Novartis NOVN.S to develop drugs for immune-mediated diseases

** The deal includes an upfront payment of $120 million to Monte Rosa, with the company eligible for a total of up to $5.7 billion in milestones and option payments across programs

** Wedbush analyst Robert Driscoll says the deal represents additional validation of Monte Rosa's molecular glue degrader discovery platform from an existing large‑pharma partner

** U.S.-listed shares of Novartis down 1% at $122.81

** Including session move, GLUE down 6.6%, NVS up 26% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI